Market Cap (In SEK)
14.75 Million
Revenue (In SEK)
-
Net Income (In SEK)
-30.87 Million
Avg. Volume
5.49 Million
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0012-0.0456
- PE
- -
- EPS
- -
- Beta Value
- 0.526
- ISIN
- SE0015961016
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Marcus Larsson Ph.D.
- Employee Count
- -
- Website
- https://www.amniotics.com
- Ipo Date
- 2021-07-06
- Details
- Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of inflammatory and fibrotic lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; and CutiStem for the treatment of dermatological indications. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
More Stocks
-
VTXPFVictrex plc
VTXPF
-
COPHFCreso Pharma Limited
COPHF
-
BREBBrederode SA
BREB
-
CDLCDRL S.A.
CDL
-
KFINTECHKFin Technologies Limited
KFINTECH
-
ACCELERATEACCELERATEBS INDIA LIMITED
ACCELERATE
-
FIHO12FibraHotel
FIHO12
-
OAMCFOverActive Media Corp.
OAMCF